Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients

20 Feb 2019

Abstract excerpt

) CML patients showing conspicuous expression of BCR-ABL gene were treated with imatinib. At the end of 3 months, 21/62 (33.87%) patients did not obtain complete hematological response (CHR) and also showed no significant decrease in BCR-ABL gene expression. In all the imatinib-resistant patients BCR-ABL gene was PCR amplified and sequenced. The sequence analysis showed four novel missense mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30787317
DOI: 10.1038/s41598-019-38672-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patientsPMID 30787317Read ↗

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.Semantic proximity Read ↗

Mutation Profiling of BCR-ABL Kinase Domain in Chronic Myeloid Leukaemia Patients with Imatinib ResistanceSemantic proximity Read ↗

Mechanisms and implications of imatinib resistance mutations in BCR-ABLSemantic proximity Read ↗

Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.Semantic proximity Read ↗

Advances in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: The Evolving Role of Bcr–Abl Mutations and Mutational AnalysisSemantic proximity Read ↗

Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.Semantic proximity Read ↗

Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependentSemantic proximity Read ↗

Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.Semantic proximity Read ↗

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcomeSemantic proximity Read ↗

Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and BeyondSemantic proximity Read ↗

Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.Semantic proximity Read ↗

Detection of BCR-ABL mutations and resistance to imatinib mesylate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.